O aspecto médico dos efeitos adversos da fumaça do tabaco na saúde humana
DOI:
https://doi.org/10.18270/rsb.v12i2.4162Palavras-chave:
Fumaça de cigarro, Doenças cardiovasculares, Problemas neurológicos, Doenças pulmonares obstrutivas, Asma, Câncer de pulmãoResumo
De acordo com os Centros de Controle e Prevenção de Doenças, há uma taxa anual de 7 milhões de mortes por causa do uso do tabaco, e essa taxa deve aumentar para 8 milhões de mortes em 2030 em virtude de complicações de saúde relacionadas ao tabagismo. Além disso, é patético saber que quase mais de 23% dos alunos do ensino médio usam tabaco, que se manteve no ritmo atual; cerca de 5,6 milhões de adolescentes estariam vulneráveis à morte, conforme mencionado pela Organização Mundial da Saúde. Por outro lado, os fumantes não apenas prejudicam a si mesmos, mas também aumentam a incidência de pneumonia, asma e bronquite para fumantes passivos, que por sinal contribuem para o desenvolvimento de câncer de pulmão e doenças cardiovasculares. Além disso, a síndrome da morte infantil e o câncer de pulmão de crescimento lento são prevalentes em crianças com exposição contínua ao fumo passivo. Esses efeitos adversos surgem da mistura complexa de produtos químicos presentes em partículas de tamanho submícron suspensas na fumaça do cigarro, como monóxido de carbono, benzeno, óxidos de nitrogênio e outros gases. Assim, parece que o tabagismo vem se espalhando mundialmente como uma epidemia com devastadores distúrbios letais representados em diversas doenças pulmonares, neurológicas e cardiovasculares. Portanto, este artigo discute os efeitos nocivos da fumaça do tabaco na saúde humana de acordo com as modernas tecnologias genéticas avançadas utilizadas em investigações exploratórias para a relação entre o tabagismo e o surgimento de doenças humanas.
Downloads
Referências
Kirby JB: The influence of parental separation on smoking initiation in adolescents. J Health Soc Behav 43: 56–71, 2002. https://doi.org/10.2307/3090245
Trends in cigarette smoking among high school students – United States, 1991–1999. MMWR Morb Mortal Wkly Rep 49: 755–758, 2000.
John U, Hanke M: Tobacco smoking attributable mortality in Germany. Gesundheitsaesen 63: 363–369, 2001.
https://doi.org/10.1055/s-2001-15684
Criado-Alvarez JJ, Morant Ginestar C, de Lucas Veguillas A. Mortality attributable to tobacco consumption in the years 1987 and 1997 in Castilla la Mancha, Spain. Rev Esp Salud Publica 2002;76:27–36.
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1135-57272002000100004&lng=es.
Lam TH, Jiang CQ, Ho SY, Zhang WS, Liu WW, He JM: Smoking and mortality in 81,344 drivers in Guangzhou, China. Occup Environ Med. 2002;59:135–138. https://doi.org/10.1136/oem.59.2.135
Marable S, Crim C, Dennis GC, Epps RP, Freeman H, Mills S, Coolchan ET, Robinson L, Robinson R, Cole L, Payne PH: Tobacco control: Consensus report of the National Medical Association. J Natl Med Assoc. 2002;94: 78–87.
Turner J, Page-Shafer K, Chin DP, Osmond D, Mossar M, Markstein L, Huitsing J, Barnes S, Clemente V, Chesney M: Pulmonary Complications of HIV Iinfection Study Group: Adverse impact of cigarette smoking on dimensions of health-related quality of life in persons with HIV infection. AIDS Patient Care STDS. 2001;15:615–624.
Vogt MT, Hanscom B, Lauerman WC, Kang JD: Influence of smoking on the health status of spinal patients: The National Spine Network database. Spine 27: 313–319, 2002. https://doi.org/10.1089/108729101753354617
Berard RM, Lockhart IA, Boermeester F, Tredoux C: Cigarette smoking in an adolescent psychiatric population. S Afr Med J 2002;92: 58–61.
Platts-Mills TAE, De Weck AL. House dust mites: A world wide problem. J Allergy Clin Immunol.
;83:416–427.
Auerbach O, Hammond EL, Garfinker L, Benante C: Relation of smoking and age to emphysema. Whole-lung section study. N Eng J Med. 1972;286:853-857. https://doi.org/10.1056/NEJM197204202861601
Mukherjee S, Das SK: Effects of cigarette smoke exposure on the binding capacity of β-adrenergic receptors in guinea pig alveolar type II cells. FASEB J 1992;6:259.
Laniado-Laborín R. Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century. Int J Environ Res Public Health. 2009 Jan;6(1):209-24. https://doi.org/10.3390/ijerph6010209. Epub 2009 Jan 9. PMID: 19440278; PMCID: PMC2672326.
Haagsman HP, Van Golde LM. Lung surfactant and pulmonary toxicology. Lung 1985;163:275-303.
https://doi.org/ 10.1007/BF00180279
Mancini NM, Bene MC, Gerard H, Chabot F, Faure G, Polu JM, Lesur O. Early effects of short-time cigarette smoking on the human lung: A study of bronchoalveolar lavage fluids. Lung 1993;171:277-291. https://doi.org/ 10.1186/1617-9625-2-1-3
Le Mesurier SM, Stewart BW, Lykke AW. Injury to type-2 pneumocytes in rats exposed to cigarette smoke. Environ Res. 1981;24: 207-217. https://doi.org/10.1016/0013-9351(81)90146-8.
Zetterberg G, Curstedt T, Eklund A. A possible alteration of surfactant in broncho-alveolar lavage fluid from healthy smokers compared to non-smokers and patients with sarcoidosis. Sarcoidosis 1995;12:46-50.Subramaniam S, Bummer P, Gairola CG. Biochemical and biophysical characterization of pulmonary surfactant in rats exposed chronically to cigarette smoke. Fundam Appl Toxicol 1995;27:63-69. https://doi.org/ 10.1165/ajrcmb.25.6.4458
Wang H, Liu X, Umino T, Skold CM, Zhu Y, Kohyama T, Spurzem JR, Romberger DJ, Rennard SI. Cigarette smoke inhibits human bronchial epithelial cell repair processes. Am J Respir Cell Mol Biol 2001;25: 772-779. https://doi.org/10.1165/ajrcmb.25.6.4458
Hunninghake GW, Crystal RG. Cigarette smoking and lung destruction. Am Rev Respir Dis.
;128:833-838. https://doi.org/10.1164/arrd.1983.128.5.833.
Ulrik CS, Lange P. Cigarette smoking and asthma. Monaldi Arch Chest Dis. 2001;56:349-353.
Mukherjee S, Woods L, Weston Z, Williams AB, Das SK: The effect of mainstream and sidestream cigarette smoke exposure on oxygen defense mechanisms of guinea pig erythrocytes. J Biochem Toxicology.1993;8:119-125.
https://doi.org/ 10.1002/jbt.2570080303.
Louie D. The effects of cigarette smoking on cardiopulmonary function and exercise tolerance in
teenagers. Can Respir J 2001;8: 289–291. https://doi.org/ 10.1155/2001/701384.
Gladston M, Feldman JG, Levytska V, Magnusson B. Antioxidant activity of serum ceruloplasmin and transferring available iron-binding capacity in smokers and non-smokers. Am Rev Respir Dis. 1987;135:783– 787, 1987.
https://doi.org/10.1164/arrd.1987.135.4.783.
Strain JJ, Carville DGM, Barker ME, Thompson KA, Welch RW, Young P, Rice DA. Smoking and blood antioxidant enzyme activities. Biochem Soc Trans. 1989;17:497–498. https://doi.org/10.1002/jbt.2570080303
McGowan SE, Henley SA. Iron and ferritin contents and distribution in human alveolar macrophages.
J Lab Clin Med 1988;111: 611–617. https://doi.org/10.2147/COPD.S138457.
Criqui MH, Cowan LD, Tyroler HA, Bangdiwala S, Heiss G, Wallace RB, Cohn R. Lipoproteins as mediators for the effects of alcohol consumption and cigarette smoking on cardiovascular mortality: results from the Lipid Research Clinics Follow-up Study. American Journal of Epidemiology. 1987;126(4):629–37. https://doi.org/10.1093/oxfordjournals.aje.a114702.
Dagenais GR, Robitaille NM, Lupien PJ, Christen A, Gingras S, Moorjani S, Meyer F, Rochon J. First coronary heart disease event rates in relation to major risk factors: Quebec Cardiovascular Study. Can J Cardiol. 1990;6(7):274–80.
Haustein KO. Health consequences of passive smoking. Z Arztl Fortbild Qualitatssich 2001;95:377–386, 2001.
Eliasson M, Lundblad D, Hagg E. Cardiovascular risk factors in young snuff-users and cigarette smokers. J Intern Med. 1991;230(1):17–22. https://doi.org/10.1111/j.1365-2796.1991.tb00401.x.
Ezzati M, Henley SJ, Thun MJ, Lopez AD. Role of smoking in global and regional cardiovascular mortality. Circulation 2005;112(4):489–97.https://doi.org/10.1161/CIRCULATIONAHA.104.521708
Iribarren C, Tekawa IS, Sidney S, Friedman GD. Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men. N Engl J Med. 1999;340(23):1773–80. https://doi.org/10.1056/NEJM199906103402301
Joseph AM, Fu SS. Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Prog Cardiovascular Dis. 2003;45(6):429–41. https://doi.org/10.1053/pcad.2003.YPCAD14.
Kannel WB, Higgins M. Smoking and hypertension as predictors of cardiovascular risk in population studies. J Hypertens Suppl. 1990;8( Suppl 5):S3–S8.
Koenig W, Sund M, Fröhlich M, Fischer H-G, Löwel H, Döring A, Hutchinson WL, Pepys MB. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999 Jan 19;99(2):237-42. https://doi.org/ 10.1161/01.cir.99.2.237.
Krumholz HM, Cohen BJ, Tsevat J, Pasternak RC, Weinstein MC. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol. 1993 Nov 15;22(6):1697-702. https://doi.org/10.1016/0735-1097(93)90598-u.
Kiyohara Y, Ueda K, Fujishima M. Smoking and cardiovascular disease in the general population in Japan. J Hypertens Suppl. 1990;8(Suppl 5):S9–S15.
Kannel WB, McGee DL, Castelli WP. Latest perspectives on cigarette smoking and cardiovascular disease: the Framingham Study. J Cardiac Rehab. 1984;4(7):267.
Kugiyama K, Yasue H, Ohgushi M, Motoyama T, Kawano H, Inobe Y, Hirashima O, Sugiyama S. Deficiency in nitric oxide bioactivity in epicardial coronary arteries of cigarette smokers. J Am Coll Cardiol. 1996;28(5):1161–7.
https://doi.org/ 10.1016/S0735-1097(96)00325-7.
Law MR, Wald NJ. Environmental tobacco smoke and ischemic heart disease. Progress Cardiovasc Dis. 2003;46(1):31–8.
https://doi.org/10.1016/S0033-0620(03)00078-1
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298(10):1180–8. https://doi.org/10.1001/jama.298.10.1180.
Lightwood J. Economics of smoking and cardiovascular disease. Progress Cardiovasc Dis.
;46(1):39–78. https://doi.org/10.1016/S0033-0620(03)00077-X
Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol. 1997;96(1):168–73. https://doi.org/10.1046/j.1365-2141.1997.8532481.x.
Lu JT, Creager MA. The relationship of cigarette smoking to peripheral arterial disease. Rev Cardiovasc Med. 2004;5(4):189–93.
Mahmarian JJ, Moyé LA, Nasser GA, Nagueh SF, Bloom MF, Benowitz NL, Verani MS, Byrd WG, Pratt CM. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol. 1997;30(1):125-130.
Metz L, Waters DD. Implications of cigarette smoking for the management of patients with acute coronary syndromes. Prog Cardiovasc Dis. 2003 Jul-Aug;46(1):1-9. https://doi.org/10.1016/s0033-0620(03)00075-6.
Meyers DG, Neuberger JS, He J. Cardiovascular effects of bans on smoking in public places: a systematic review and meta-analysis. J Am Coll Cardiol. 2009 Sep 29;54(14):1249-55. https://doi.org/10.1016/j.jacc.2009.07.022. Erratum in: J Am Coll Cardiol. 2009 Nov
;54(20):1902.
Neunteufl T, Heher S, Kostner K, Mitulovic G, Lehr S, Khoschsorur G, Schmid RW, Maurer G, Stefenelli T. Contribution of nicotine to acute endothelial dysfunction in long-term smokers. J Am Coll Cardiol. 2002 Jan 16;39(2):251-6.
https://doi.org/10.1016/s0735-1097(01)01732-6.A.
Aromaa, & S. Koskinen (Eds.), (1996). Health and functional capacity in Finland. Baseline results of the Health 2000 Health Examination Survey. Helsinki: National Public Health Institute, Department of Health and Functional Capacity.
Choi GSB, Krishnan JKR. Cigarette smoke and related risk factors in neurological disorders: An update. Biomed Pharmacother. 2017 Jan;85:79-86 https://doi.org/10.1016/j.biopha.2016.11.118.
Platts-Mills TAE, De Weck AL. House dust mites: A world wide problem. J Allergy Clin Immunol1989;83:416–427.
https://doi.org/10.1016/0091-6749(89)90128-0.
Fratiglioni L, Wang HX: Smoking and Parkinson’s and Alzheimer’s disease: Review of the epidemiological studies. Behav Brain Res 2000;113:117–120. https://doi.org/ 10.1016/s0166-4328(00)00206-0
Almeida OP, Hulse GK, Lawrence D, Flickler L: Smoking as a risk factor for Alzheimer’s disease: Contrasting evidence from a systematic review of case-control and cohort studies. Addiction 2002;9:15–28.
https://doi.org/10.1046/j.1360-0443.2002.00016.x.
Charpin D, Kleisbauer JP, Lanteaume A, Razzouk H, Vervloet D, Toumi M, Faraj F, Charpin J: Asthma and allergy to house-dust mites in populations living in high altitude. Chest 1988;93:758–761. https://doi.org/10.1378/chest.93.4.758.
Andrae SO, Axelson O, Bjorksten B, Fredriksson M, Kjellman NIM: Symptoms of bronchial hyperreactivity and asthma in relation to environmental factors. Arch Dis Child 1988;63: 473–478. https://doi.org/10.1136/adc.63.5.473.
Tager IB. Passive smoking-bronchial responsiveness and atopy. Am Rev Respir Dis 1988;138:507–579.
https://doi.org/ 10.1164/ajrccm/138.3.507.
Garcia-Closas M, Kelsey KT, Wiencke JK, Xu X, Wain JC, Christiani DC. A case control study of cytochrome P450 1A1, glutathione S transferase M1, cigarette smoking and lung cancer susceptibility. Cancer Causes Control 1997;8:544-53.
https://doi.org/ 10.1023/a:1018481910663.
Vineis P, Bartsch H, Caporaso N, et al. Genetically based N-acetyltransferase metabolic polymorphism and low level environmental exposure to carcinogens. Nature. 1994;369:154-6. https://doi.org/10.1038/369154a0.
Brockmöller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996;56:3915-25.
Rebbeck T. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733-43.
Hirvonen A, Nylund L, Kociba P, Husgafvel-Pursiainen DK, Vainio H. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers. Carcinogenesis 1994;15:813-5. https://doi.org/ 10.1093/carcin/15.5.813.
Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J Natl Canc Inst. 1995;87:902-7. https://doi.org/10.1093/jnci/87.12.902.
Glantz S, Parmley WW. Passive smoking and heart disease: Mechanisms and risk. JAMA. 1995;273:1047–53.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 2004;83:1–1438.
Howard G, Wagenknecht LE, Diez-Roux A, et al. Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA. 1998;279:119–24. https://doi.org/10.1001/jama.279.2.119.
He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK. Passive smoking and the risk of coronary heart disease – a meta-analysis of epidemiologic studies. N Engl J Med. 1999;340:920–6. https://doi.org/10.1056/NEJM199903253401204.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2023 Universidad El Bosque
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
El (Los) autor(es) certifican que es(son) el (los) autor(es) originario(s) del trabajo que se esta presentando para posible publicación en la Revista Salud Bosque de la Facultad Escuela Colombiana de Medicina de la Universidad El Bosque, puesto que sus contenidos son producto de su directa contribución intelectual.
Todos los datos y las referencias a materiales ya publicados deben estar debidamente identificados con su respectivo crédito e incluidos en las notas bibliográficas y en las citas que se destacan como tal y, en los casos que así lo requieran, deben contar con las debidas autorizaciones de quienes poseen los derechos patrimoniales.
El (Los) autor(es) declara(n) que todos los materiales que se presentan están totalmente libres de derecho de autor y, por lo tanto, se hace(n) responsable(s) de cualquier litigio o reclamación relacionada con derechos de propiedad intelectual, exonerando de responsabilidad a la Universidad El Bosque
